This clinical trial studies stress urinary incontinence, a condition where urine leaks during physical activities such as coughing, sneezing, laughing, or exercising. This type of incontinence occurs when the muscles that support the bladder and control urine release become weakened. The study focuses specifically on women who also have obesity or are overweight, as excess body weight can place additional pressure on the bladder and pelvic muscles, potentially worsening incontinence symptoms.
The trial investigates whether a medication called Orforglipron, taken as a tablet once daily by mouth, can help reduce the number of incontinence episodes experienced each week. Orforglipron belongs to a class of medications known as GLP-1 receptor agonists, which work by mimicking a natural hormone in the body that helps regulate appetite and body weight. By potentially helping participants lose weight, this medication may also reduce pressure on the bladder and improve incontinence symptoms. Some participants will receive placebo instead of the active medication.
The study aims to determine if Orforglipron is more effective than placebo in decreasing the frequency of urinary leakage episodes. Participants will take one tablet daily throughout the treatment period, and their incontinence episodes will be monitored and recorded. This is a Phase 3 trial sponsored by Eli Lilly, designed to evaluate both the effectiveness and safety of the medication in this specific patient population.
Czechia 
Poland 
Romania 